SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001104659-21-009098
Filing Date
2021-01-29
Accepted
2021-01-29 09:07:03
Documents
4
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G tm214547d1_sc13g.htm SC 13G 61619
2 EXHIBIT 99.1 tm214547d1_ex99-1.htm EX-99.1 15442
3 EXHIBIT 99.2 tm214547d1_ex99-2.htm EX-99.2 6068
4 EXHIBIT 99.3 tm214547d1_ex99-3.htm EX-99.3 7052
  Complete submission text file 0001104659-21-009098.txt   91774
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 180 KIMBALL WAY SUITE 200 SOUTH SAN FRANCISCO CA 94080
Business Address 180 KIMBALL WAY SUITE 200 SOUTH SAN FRANCISCO CA 94080 (650)-822-5500
Annexon, Inc. (Subject) CIK: 0001528115 (see all company filings)

IRS No.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91583 | Film No.: 21568376
SIC: 2834 Pharmaceutical Preparations